Skip to main content
Top
Published in: Clinical and Experimental Nephrology 2/2016

01-04-2016 | Original Article

Involvement of the renin–angiotensin system in the development of nephrogenic systemic fibrosis-like lesions in the RenTag mouse model

Authors: Sandra Sexton, Ryan Tulowitzki, Craig A. Jones, Silvi Shah, George Hajduczok, Kenneth W. Gross, Mandip Panesar

Published in: Clinical and Experimental Nephrology | Issue 2/2016

Login to get access

Abstract

Background

Renin–angiotensin system (RAS) activation increases angiotensin II production stimulating profibrotic factors, especially in the setting of chronic kidney disease. Nephrogenic systemic fibrosis (NSF) has been associated with gadolinium (Gd) exposure and renal failure. RAS involvement in NSF is unclear compared to transforming growth factor beta and Smad. RenTag mice were chosen to investigate the role of RAS in NSF-like dermal fibrosis because they demonstrated dermal fibrosis at birth, perturbations of RAS in subcutaneous tissue, and renal failure within 4 weeks of age.

Methods

Wild-type and RenTag mice were injected weekly with a supratherapeutic dose of intravenous gadodiamide (3.0 mmol/kg body weight) and killed at 12 weeks of age for skin and kidney histology.

Results

RenTag mice had elevated BUN levels, pitted kidneys, and glomerular damage. RenTag mice skin revealed an increased density of fibroblasts, no mucopolysaccharide deposits, and increased collagen fibril density regardless of Gd exposure. Skin and kidney histopathology of wild-type mice were normal regardless of Gd exposure. CD34 positivity was higher in RenTag compared to wild-type.

Conclusions

Since RenTag dermal lesions remained unchanged after gadolinium exposure in the setting of renal failure, this animal model suggests perturbations of subcutaneous RAS may be involved in Gd-naïve dermal fibrosis.
Literature
1.
go back to reference Aros C, Remuzzi G. The Renin–angiotensin system in progression, remission and regression of chronic nephropathies. J Hypertens Suppl. 2002;20:45–53.CrossRef Aros C, Remuzzi G. The Renin–angiotensin system in progression, remission and regression of chronic nephropathies. J Hypertens Suppl. 2002;20:45–53.CrossRef
2.
go back to reference Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of Renin–angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int. 2005;68:57–65.CrossRef Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of Renin–angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int. 2005;68:57–65.CrossRef
3.
go back to reference Kanno Y, Takenaka T, Nakamura T, Suzuki H. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors. Clin J Am Soc Nephrol. 2006;1:730–7.CrossRefPubMed Kanno Y, Takenaka T, Nakamura T, Suzuki H. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors. Clin J Am Soc Nephrol. 2006;1:730–7.CrossRefPubMed
4.
go back to reference Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Inter Med. 2008;148:30–48.CrossRef Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Inter Med. 2008;148:30–48.CrossRef
5.
go back to reference Lewis E, Hunsicker L, Clarke W, Pohl M, Lewis J, Ritz E, Rohde R, Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.CrossRefPubMed Lewis E, Hunsicker L, Clarke W, Pohl M, Lewis J, Ritz E, Rohde R, Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.CrossRefPubMed
6.
go back to reference Li P, Leung C, Chow K, Cheng Y, Fung S, Mak S, Tang A, Yung J, Yu A, Szeto C. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis. 2006;47:751–60.CrossRefPubMed Li P, Leung C, Chow K, Cheng Y, Fung S, Mak S, Tang A, Yung J, Yu A, Szeto C. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis. 2006;47:751–60.CrossRefPubMed
7.
go back to reference Ruiz-Ortega M, Egido J. Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int. 1997;52:1497–510.CrossRefPubMed Ruiz-Ortega M, Egido J. Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int. 1997;52:1497–510.CrossRefPubMed
8.
go back to reference Kagami S, Border W, Miller D, Noble N. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest. 1994;93:2431–7.CrossRefPubMedPubMedCentral Kagami S, Border W, Miller D, Noble N. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest. 1994;93:2431–7.CrossRefPubMedPubMedCentral
9.
go back to reference Iwano M, Plieth D, Danoff T, Xue C, Okada H, Neilson E. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest. 2002;110:341–50.CrossRefPubMedPubMedCentral Iwano M, Plieth D, Danoff T, Xue C, Okada H, Neilson E. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest. 2002;110:341–50.CrossRefPubMedPubMedCentral
10.
go back to reference Sanchez-Lopez E, Rodrigues D, Rodriguez V, Reyego M, Rodriguez G, Lavoz B, Mezzano S, Egido J, Ortiz A, Ruiz-Ortega M. Connective tissue growth factor (CTGF): a key factor in the onset and progression of kidney damage. Nefrologia. 2009;29:382–91.PubMed Sanchez-Lopez E, Rodrigues D, Rodriguez V, Reyego M, Rodriguez G, Lavoz B, Mezzano S, Egido J, Ortiz A, Ruiz-Ortega M. Connective tissue growth factor (CTGF): a key factor in the onset and progression of kidney damage. Nefrologia. 2009;29:382–91.PubMed
11.
go back to reference Schneider A, Panzer U, Zahner G, Wenzel U, Wolf G, Thaiss F, Helmchen U, Stahl R. Monocyte chemoattractant protein-1 mediates collagen deposition in experimental glomerulonephritis by transforming growth factor-beta. Kidney Int. 1999;56:135–44.CrossRefPubMed Schneider A, Panzer U, Zahner G, Wenzel U, Wolf G, Thaiss F, Helmchen U, Stahl R. Monocyte chemoattractant protein-1 mediates collagen deposition in experimental glomerulonephritis by transforming growth factor-beta. Kidney Int. 1999;56:135–44.CrossRefPubMed
12.
go back to reference Wolf G, Haberstroh U, Neilson E. Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol. 1992;140:95–107.PubMedPubMedCentral Wolf G, Haberstroh U, Neilson E. Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol. 1992;140:95–107.PubMedPubMedCentral
13.
go back to reference Wolf G, Zahner G, Schroeder R, Stahl R. Transforming growth factor beta mediates the angiotensin-II-induced stimulation of collagen type IV synthesis in cultured murine proximal tubular cells. Nephrol Dial Transplant. 1996;11:263–9.CrossRefPubMed Wolf G, Zahner G, Schroeder R, Stahl R. Transforming growth factor beta mediates the angiotensin-II-induced stimulation of collagen type IV synthesis in cultured murine proximal tubular cells. Nephrol Dial Transplant. 1996;11:263–9.CrossRefPubMed
14.
go back to reference Wolf G. Angiotensin II as a mediator of tubulointerstitial injury. Nephrol Dial Transplant. 2000;15:61–3.CrossRefPubMed Wolf G. Angiotensin II as a mediator of tubulointerstitial injury. Nephrol Dial Transplant. 2000;15:61–3.CrossRefPubMed
15.
go back to reference Cowper S, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Euro J Radiol. 2008;66:191–9.CrossRef Cowper S, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Euro J Radiol. 2008;66:191–9.CrossRef
16.
go back to reference Galan A, Cowper S, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol. 2006;18:614–7.CrossRefPubMed Galan A, Cowper S, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol. 2006;18:614–7.CrossRefPubMed
17.
go back to reference Cowper S, Bucala R, Leboit P. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis—setting the record straight. Semin Arthritis Rheum. 2006;35:208–10.CrossRefPubMed Cowper S, Bucala R, Leboit P. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis—setting the record straight. Semin Arthritis Rheum. 2006;35:208–10.CrossRefPubMed
18.
go back to reference Jimenez S, Artlett C, Sandorfi N, Derk C, Latinis K, Haddad R, Shanahan J. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum. 2004;50:2660–6.CrossRefPubMed Jimenez S, Artlett C, Sandorfi N, Derk C, Latinis K, Haddad R, Shanahan J. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum. 2004;50:2660–6.CrossRefPubMed
19.
go back to reference Mendoza F, Artlett C, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez A. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum. 2006;35:238–49.CrossRefPubMedPubMedCentral Mendoza F, Artlett C, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez A. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum. 2006;35:238–49.CrossRefPubMedPubMedCentral
20.
go back to reference Jacob HJ, Sigmund CD, Shockley TR, Gross KW, Dzau VJ. Renin promoter SV40 T-antigen transgenic mouse. A model of primary renal vascular hyperplasia. Hypertension. 1991;17(6 Pt 2):1167–62.CrossRefPubMed Jacob HJ, Sigmund CD, Shockley TR, Gross KW, Dzau VJ. Renin promoter SV40 T-antigen transgenic mouse. A model of primary renal vascular hyperplasia. Hypertension. 1991;17(6 Pt 2):1167–62.CrossRefPubMed
21.
go back to reference Sigmund C, Okuyama K, Ingelfinge, Jones C, Mullins J, Kane C, Kim U, Wu C, Kenny L, Rustum Y. Isolation and characterization of renin-expressing cell lines from transgenic mice containing a renin-promotor viral oncogene fusion construct. J Biochem. 1990;265:19916–22. Sigmund C, Okuyama K, Ingelfinge, Jones C, Mullins J, Kane C, Kim U, Wu C, Kenny L, Rustum Y. Isolation and characterization of renin-expressing cell lines from transgenic mice containing a renin-promotor viral oncogene fusion construct. J Biochem. 1990;265:19916–22.
22.
go back to reference Cowper S, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol. 2003;4:358.CrossRef Cowper S, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol. 2003;4:358.CrossRef
23.
go back to reference Kucher C, Xu X, Pasha T, Elenitsas R. Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema. J Cutan Pathol. 2005;32:484–90.CrossRefPubMed Kucher C, Xu X, Pasha T, Elenitsas R. Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema. J Cutan Pathol. 2005;32:484–90.CrossRefPubMed
24.
go back to reference Gagnon R, Duguid W. A reproducible model for chronic renal failure in the mouse. Urol Res. 1983;11:11–4.CrossRefPubMed Gagnon R, Duguid W. A reproducible model for chronic renal failure in the mouse. Urol Res. 1983;11:11–4.CrossRefPubMed
25.
go back to reference Sigmund C, Jones C, Fabian J, Mullins J, Gross K. Tissue and cell specific expression of a renin promoter-reporter gene construct in transgenic mice. Biochem Biophys Res Commun. 1990;170:344–50.CrossRefPubMed Sigmund C, Jones C, Fabian J, Mullins J, Gross K. Tissue and cell specific expression of a renin promoter-reporter gene construct in transgenic mice. Biochem Biophys Res Commun. 1990;170:344–50.CrossRefPubMed
26.
go back to reference Sigmund C, Jones C, Jacob H, Ingelfinger J, Kim U, Gamble D, Dzau V, Gross K. Pathophysiology of vascular smooth muscle in renin-promotor-T-antigen transgenic mice. Am J Physiol Renal Physiol. 1991;260:F249–57. Sigmund C, Jones C, Jacob H, Ingelfinger J, Kim U, Gamble D, Dzau V, Gross K. Pathophysiology of vascular smooth muscle in renin-promotor-T-antigen transgenic mice. Am J Physiol Renal Physiol. 1991;260:F249–57.
27.
go back to reference Stawski L, Han R, Bujor A, Trojanowska M. Angiotensin II induces skin fibrosis: a novel mouse model of dermal fibrosis. Arthritis Res Ther. 2012;14:R194.CrossRefPubMedPubMedCentral Stawski L, Han R, Bujor A, Trojanowska M. Angiotensin II induces skin fibrosis: a novel mouse model of dermal fibrosis. Arthritis Res Ther. 2012;14:R194.CrossRefPubMedPubMedCentral
28.
go back to reference Ito Y, Aten J, Bende R, Oemar B, Rabelink T, Weening J, Goldschmeding R. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int. 1998;53:853–61.CrossRefPubMed Ito Y, Aten J, Bende R, Oemar B, Rabelink T, Weening J, Goldschmeding R. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int. 1998;53:853–61.CrossRefPubMed
29.
go back to reference Mezzano S, Ruiz-Orega M, Egido J. Angiotensin II and renal fibrosis. Hypertension. 2001;38:635–8.CrossRefPubMed Mezzano S, Ruiz-Orega M, Egido J. Angiotensin II and renal fibrosis. Hypertension. 2001;38:635–8.CrossRefPubMed
30.
go back to reference Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido J. Proinflammatory actions of angiotensins. Curr Opin Nephrol and Hypertens. 2001;10:321–9.CrossRef Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido J. Proinflammatory actions of angiotensins. Curr Opin Nephrol and Hypertens. 2001;10:321–9.CrossRef
31.
go back to reference Sigmund C, Jones C, Mullins J, Kim U, Gross K. Expression of murine renin genes in subcutaneous connective tissue. Proc Natl Acad Sci. 1990;87:7993–7.CrossRefPubMedPubMedCentral Sigmund C, Jones C, Mullins J, Kim U, Gross K. Expression of murine renin genes in subcutaneous connective tissue. Proc Natl Acad Sci. 1990;87:7993–7.CrossRefPubMedPubMedCentral
32.
go back to reference Langer R, Lorke D, Neidl van Gorkom K, Petroianu G, Azimullah S, Singh S, Fuchsjager M. In an animal model nephrogenic systemic fibrosis cannot be induced by intraperitoneal injection of high-dose gadolinium based contrast agents. European J Radiol. 2012;81:2562–7.CrossRef Langer R, Lorke D, Neidl van Gorkom K, Petroianu G, Azimullah S, Singh S, Fuchsjager M. In an animal model nephrogenic systemic fibrosis cannot be induced by intraperitoneal injection of high-dose gadolinium based contrast agents. European J Radiol. 2012;81:2562–7.CrossRef
33.
go back to reference Grant D, Johnson H, Juelsrud A, Lovhaug D. Effects of gadolinium contrast agents in naïve and nephrectomized rats: relevance to nephrogenic systemic fibrosis. Acta Radiol. 2009;50:156–69.CrossRefPubMed Grant D, Johnson H, Juelsrud A, Lovhaug D. Effects of gadolinium contrast agents in naïve and nephrectomized rats: relevance to nephrogenic systemic fibrosis. Acta Radiol. 2009;50:156–69.CrossRefPubMed
34.
go back to reference Wahba I, Simpson E, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant. 2007;7:2425–32.CrossRefPubMed Wahba I, Simpson E, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant. 2007;7:2425–32.CrossRefPubMed
35.
go back to reference Kelly B, Petitt M, Sanchez R. Nephrogenic systemic fibrosis is associated with transforming growth factor beta and Smad without evidence of Renin–angiotensin system involvement. J Am Acad Dermatol. 2008;58:1025–30.CrossRefPubMed Kelly B, Petitt M, Sanchez R. Nephrogenic systemic fibrosis is associated with transforming growth factor beta and Smad without evidence of Renin–angiotensin system involvement. J Am Acad Dermatol. 2008;58:1025–30.CrossRefPubMed
Metadata
Title
Involvement of the renin–angiotensin system in the development of nephrogenic systemic fibrosis-like lesions in the RenTag mouse model
Authors
Sandra Sexton
Ryan Tulowitzki
Craig A. Jones
Silvi Shah
George Hajduczok
Kenneth W. Gross
Mandip Panesar
Publication date
01-04-2016
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 2/2016
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-015-1141-z

Other articles of this Issue 2/2016

Clinical and Experimental Nephrology 2/2016 Go to the issue